However, the use of CTLA-4 checkpoint inhibitors has been complicated by the emergence of autoimmunity, including demyelination.1 We report the first case of biopsy-proven central nervous system (CNS) inflammatory demyelination in the context of primary immunodeficiency and a novel CTLA-4 variant. Here, CTLA4 is linked to Peripheral demyelination.